Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis
Completed
- Conditions
- Atopic Dermatitis
- Registration Number
- NCT00098150
- Lead Sponsor
- Novartis
- Brief Summary
This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
- Consenting patients who participated in the core clinical trial
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term safety outcomes of pimecrolimus in atopic dermatitis patients from NCT00098150?
How does pimecrolimus compare to calcineurin inhibitors in managing atopic dermatitis flare-ups?
What biomarkers correlate with sustained response to pimecrolimus in atopic dermatitis?
Are there specific adverse events reported in pimecrolimus-treated atopic dermatitis patients post-trial?
What is the role of pimecrolimus in the broader context of calcineurin inhibitor alternatives for atopic dermatitis?